Dr. Mintz brings a wealth of experience to his role as Chief Medical Officer at Verax. He is former president of the AABB who served as a tenured professor of Pathology and Medicine at the University of Virginia as well as Vice Chair of Pathology.
He also served on the AABB's board of directors for nine years, and chaired and was a member of numerous AABB committees. Most recently, Dr. Mintz served as Director, Division of Hematology Clinical Review, Office of Blood Research and Review, Center for Biologics Evaluation and Research of the U.S. Food and Drug Administration.
Have a question or comment? Click here to contact me directly.
"I'm excited to work at Verax because the company shares my passion for patient safety and best transfusion practices. I'll use this blog to express my thoughts and views about current topics in transfusion medicine and how they may impact your transfusion service or blood bank."
- Paul D. Mintz, MD
FDA publishes 2017 Guidance Agenda listing Final Guidance for Bacterial Risk Control Strategies for Platelets as a top priority Learn More
CMS Modifies Permanent P-Code Allowing Outpatient Hospital Billing of the Verax PGD® Test Learn More
FDA advises testing for Zika virus in all donated blood and blood components in the US Learn More
Congressional Representatives call for broad Zika blood screening citing a cost of less than $10 per donor Learn More
Major new publication of note: "Will pathogen reduction of blood components harm more people than it helps in developed countries?" Learn More
First blood center in Texas initiates routine blood donor screening for Zika virus with new test under IND Learn More
7 Day platelet dating added to 30th Edition of the AABB Standards for Blood Banks and Transfusion Services Learn More
New Draft FDA Guidance recommends secondary testing with rapid tests and Safety Measure testing for 7-day dating